No Data
Beijing Tiantan Biological Products Corporation (600161.SH): The affiliated enterprise "subcutaneous injection of human immunoglobulin" has completed phase III clinical trials and obtained the clinical trial summary report.
On November 22, Gelonghui reported that beijing tiantan biological products corporation (600161.SH) announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as 'Chengdu Rongsheng'), has completed the phase III clinical trial of 'subcutaneous human immunoglobulin' and obtained the clinical trial summary report. The clinical research results of the subcutaneous human immunoglobulin produced by Chengdu Rongsheng show that after administration, it can maintain a more stable serum concentration of immunoglobulin G (igg) and effectively reduce the occurrence of serious bacterial infections (SBI), demonstrating good efficacy and safety for patients with primary immunodeficiency diseases (PID).
Beijing Tiantan Biological Products Corporation (600161.SH): The "Human Prothrombin Complex" developed has completed clinical ethical review, pre-clinical preparation for inclusion and other work, and officially started phase III clinical trials recently.
Gelonghui October 31st news | beijing tiantan biological products corporation (600161.SH) announced that the "Human Prothrombin Complex" developed by its subsidiary guizhou biological pharmaceutical co., ltd. of China National Pharmaceutical Group has completed the clinical ethical review, pre-clinical recruitment preparation, and officially launched phase III clinical trials in recent days.
Tiantan Biotech Report for the Third Quarter of 2024
Tiantan Biotech Earnings Report Announcement for the First Three Quarters of 2024
Beijing Tiantan Biological Products Corporation (600161.SH) affiliated enterprise obtained pharmaceutical registration certificate and passed pharmaceutical GMP compliance inspection.
beijing tiantan biological products corporation (600161.SH) announced that its parent company, china national pharmaceutical group lanzhou biological pharmaceutical limited company (hereinafter referred to as...
Beijing Tiantan Biological Products Corporation (600161.SH): The affiliated company's intravenous human immunoglobulin (pH4) has obtained a new indication clinical trial approval notice.
Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as 'Chengdu Rongsheng'), has obtained the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration. Chengdu Rongsheng has been granted permission to conduct clinical trials for new indications of its marketed product 'Intravenous Human Immunoglobulin (pH4) (10%, 50ml)'. The new indication is chronic inflammatory demyelinating polyradiculoneuropathy.
